Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia

Ayalew Tefferi, David M Dingli, Chin Yang Li, Gordon W. Dewald

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

BACKGROUND. Approximately 30-50% of patients with myelofibrosis with myeloid metaplasia (MMM) demonstrate detectable cytogenetic abnormalities, the prognostic value of which has not been completely denned by previous retrospective studies. The current prospective study addresses this issue in the context of currently accepted independent prognostic variables. METHODS. The current study is a single institution study in which patients with MMM were accrued between January 2000 and August 2001 and followed in a prospective fashion. All study patients underwent bone marrow examination with cytogenetic studies as well as comprehensive clinical and laboratory evaluation at the time of karyotype analysis. RESULTS. Among the study cohort of 81 patients (with a median age of 61 years; 54 males), the cytogenetic findings were normal in 44 patients (54%; Group 1). The remaining 37 patients (46%) demonstrated either interstitial deletions involving the long arm of chromosome 13 or 20 (9 patients; Group 2) or other abnormalities (28 patients; Group 3). All study patients were followed prospectively for a minimum of 40 months (range, 40-55 months). Survival from the time of karyotypic analysis was found to be similar between Groups 1 and 2 but was significantly worse in Group 3. Furthermore, none of the patients in Group 2 experienced leukemic transformation, whereas five patients each from the other two groups did. Multivariate analysis identified an unfavorable cytogenetic profile (Group 3), ≥ 1% circulating blasts, a hemoglobin level of <10 g/dL, and constitutional symptoms as adverse prognostic features for overall survival. CONCLUSIONS. Specific cytogenetic lesions in patients with MMM might carry an independent prognostic effect for both survival and the risk of leukemic transformation. Such information should assist in decision making when considering aggressive treatment approaches.

Original languageEnglish (US)
Pages (from-to)1656-1660
Number of pages5
JournalCancer
Volume104
Issue number8
DOIs
StatePublished - Oct 15 2005

Fingerprint

Primary Myelofibrosis
Chromosome Aberrations
Cytogenetics
Survival
Chromosomes, Human, Pair 20
Bone Marrow Examination
Chromosomes, Human, Pair 13
Karyotype
Decision Making
Hemoglobins
Cohort Studies
Multivariate Analysis
Retrospective Studies

Keywords

  • Cytogenetic abnormalities
  • Leukemic transformation
  • Myelofibrosis
  • Myeloid metaplasia
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. / Tefferi, Ayalew; Dingli, David M; Li, Chin Yang; Dewald, Gordon W.

In: Cancer, Vol. 104, No. 8, 15.10.2005, p. 1656-1660.

Research output: Contribution to journalArticle

@article{c68944d2e4064c8db7548577b082f8fd,
title = "Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia",
abstract = "BACKGROUND. Approximately 30-50{\%} of patients with myelofibrosis with myeloid metaplasia (MMM) demonstrate detectable cytogenetic abnormalities, the prognostic value of which has not been completely denned by previous retrospective studies. The current prospective study addresses this issue in the context of currently accepted independent prognostic variables. METHODS. The current study is a single institution study in which patients with MMM were accrued between January 2000 and August 2001 and followed in a prospective fashion. All study patients underwent bone marrow examination with cytogenetic studies as well as comprehensive clinical and laboratory evaluation at the time of karyotype analysis. RESULTS. Among the study cohort of 81 patients (with a median age of 61 years; 54 males), the cytogenetic findings were normal in 44 patients (54{\%}; Group 1). The remaining 37 patients (46{\%}) demonstrated either interstitial deletions involving the long arm of chromosome 13 or 20 (9 patients; Group 2) or other abnormalities (28 patients; Group 3). All study patients were followed prospectively for a minimum of 40 months (range, 40-55 months). Survival from the time of karyotypic analysis was found to be similar between Groups 1 and 2 but was significantly worse in Group 3. Furthermore, none of the patients in Group 2 experienced leukemic transformation, whereas five patients each from the other two groups did. Multivariate analysis identified an unfavorable cytogenetic profile (Group 3), ≥ 1{\%} circulating blasts, a hemoglobin level of <10 g/dL, and constitutional symptoms as adverse prognostic features for overall survival. CONCLUSIONS. Specific cytogenetic lesions in patients with MMM might carry an independent prognostic effect for both survival and the risk of leukemic transformation. Such information should assist in decision making when considering aggressive treatment approaches.",
keywords = "Cytogenetic abnormalities, Leukemic transformation, Myelofibrosis, Myeloid metaplasia, Prognosis, Survival",
author = "Ayalew Tefferi and Dingli, {David M} and Li, {Chin Yang} and Dewald, {Gordon W.}",
year = "2005",
month = "10",
day = "15",
doi = "10.1002/cncr.21358",
language = "English (US)",
volume = "104",
pages = "1656--1660",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia

AU - Tefferi, Ayalew

AU - Dingli, David M

AU - Li, Chin Yang

AU - Dewald, Gordon W.

PY - 2005/10/15

Y1 - 2005/10/15

N2 - BACKGROUND. Approximately 30-50% of patients with myelofibrosis with myeloid metaplasia (MMM) demonstrate detectable cytogenetic abnormalities, the prognostic value of which has not been completely denned by previous retrospective studies. The current prospective study addresses this issue in the context of currently accepted independent prognostic variables. METHODS. The current study is a single institution study in which patients with MMM were accrued between January 2000 and August 2001 and followed in a prospective fashion. All study patients underwent bone marrow examination with cytogenetic studies as well as comprehensive clinical and laboratory evaluation at the time of karyotype analysis. RESULTS. Among the study cohort of 81 patients (with a median age of 61 years; 54 males), the cytogenetic findings were normal in 44 patients (54%; Group 1). The remaining 37 patients (46%) demonstrated either interstitial deletions involving the long arm of chromosome 13 or 20 (9 patients; Group 2) or other abnormalities (28 patients; Group 3). All study patients were followed prospectively for a minimum of 40 months (range, 40-55 months). Survival from the time of karyotypic analysis was found to be similar between Groups 1 and 2 but was significantly worse in Group 3. Furthermore, none of the patients in Group 2 experienced leukemic transformation, whereas five patients each from the other two groups did. Multivariate analysis identified an unfavorable cytogenetic profile (Group 3), ≥ 1% circulating blasts, a hemoglobin level of <10 g/dL, and constitutional symptoms as adverse prognostic features for overall survival. CONCLUSIONS. Specific cytogenetic lesions in patients with MMM might carry an independent prognostic effect for both survival and the risk of leukemic transformation. Such information should assist in decision making when considering aggressive treatment approaches.

AB - BACKGROUND. Approximately 30-50% of patients with myelofibrosis with myeloid metaplasia (MMM) demonstrate detectable cytogenetic abnormalities, the prognostic value of which has not been completely denned by previous retrospective studies. The current prospective study addresses this issue in the context of currently accepted independent prognostic variables. METHODS. The current study is a single institution study in which patients with MMM were accrued between January 2000 and August 2001 and followed in a prospective fashion. All study patients underwent bone marrow examination with cytogenetic studies as well as comprehensive clinical and laboratory evaluation at the time of karyotype analysis. RESULTS. Among the study cohort of 81 patients (with a median age of 61 years; 54 males), the cytogenetic findings were normal in 44 patients (54%; Group 1). The remaining 37 patients (46%) demonstrated either interstitial deletions involving the long arm of chromosome 13 or 20 (9 patients; Group 2) or other abnormalities (28 patients; Group 3). All study patients were followed prospectively for a minimum of 40 months (range, 40-55 months). Survival from the time of karyotypic analysis was found to be similar between Groups 1 and 2 but was significantly worse in Group 3. Furthermore, none of the patients in Group 2 experienced leukemic transformation, whereas five patients each from the other two groups did. Multivariate analysis identified an unfavorable cytogenetic profile (Group 3), ≥ 1% circulating blasts, a hemoglobin level of <10 g/dL, and constitutional symptoms as adverse prognostic features for overall survival. CONCLUSIONS. Specific cytogenetic lesions in patients with MMM might carry an independent prognostic effect for both survival and the risk of leukemic transformation. Such information should assist in decision making when considering aggressive treatment approaches.

KW - Cytogenetic abnormalities

KW - Leukemic transformation

KW - Myelofibrosis

KW - Myeloid metaplasia

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=26444470779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444470779&partnerID=8YFLogxK

U2 - 10.1002/cncr.21358

DO - 10.1002/cncr.21358

M3 - Article

C2 - 16104040

AN - SCOPUS:26444470779

VL - 104

SP - 1656

EP - 1660

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -